Status: Recruiting
Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Sarcopenia. 2. To observe the preliminary effectiveness of CG-BM1 in treating Sarcopenia patients.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 50-85Biological sex: AllType: InterventionalSponsor: GuangZhou Cellgenes Biotechnology Co., Ltd.Updated: Oct 8, 2026Locations: 1
Eligibility criteria
1. Voluntary participation; participant or legal guardian fully understands the...
1. Known hypersensitivity to any component of CG-BM1 (human bone marrow mesenchy...